The Latest in CLL

iFCG achieves high MRD-negative remission in untreated CLL

May 30, 2017

CLL

ECG finding predicts AFib in ibrutinib-treated CLL

May 23, 2017

CLL

In good-candidate CLL, don’t wait too long for alloHCT

May 22, 2017

CLL

Ibrutinib response in CLL/SLL less affected by select risk factors

May 21, 2017

CLL

Targeted drugs transform CLL management

April 24, 2017

CLL

Venetoclax produces durable effects in relapsed/refractory CLL

March 29, 2017

CLL

Advanced CLL treatment approach depends on comorbidity burden

March 27, 2017

CLL

CLL boost in PFS came at high cost in side effects

March 8, 2017

CLL

CAR designers report high B-cell cancer response rates

March 2, 2017

Ublituximab was safe, highly active in rituximab-pretreated B-cell NHL, CLL

February 21, 2017

CLL

In CLL, specific mutation is key to ibrutinib resistance

February 13, 2017

CLL

In active CLL with deletion 17p, consider trial enrollment

February 9, 2017

CLL

Why CLL may go chemo free

February 8, 2017

CLL

AML leads percent gains in 5-year survival among leukemias

January 30, 2017

CLL

Lenalidomide maintenance extended progression-free survival in high-risk CLL

January 17, 2017

CLL